Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (301-310 of 868) with videos related to

Pageof 87
Sort By:
Blood|September 1, 2010
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Monette Aujay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple MyelomaXiaoyan Feng, Li Zhang, Chirag Acharya, et al.
Cancer Letters|February 28, 2002
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitorsMasaharu Akiyama, Osamu Yamada, Naotoshi Kanda, et al.
Nature Reviews. Disease Primers|July 21, 2017
Multiple myelomaShaji K Kumar, Vincent Rajkumar, Robert A Kyle, et al.
Future Oncology (London, England)|December 23, 2017
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study designPaul G Richardson, Michel Attal, Frank Campana, et al.
Blood|July 23, 2025
A BCMA-mRNA vaccine is a promising therapeutic for multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
British Journal of Haematology|December 1, 2010
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivoAjita V Singh, Madhavi Bandi, Monette A Aujay, et al.
Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.
Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.
Pageof 87

Showing results (301-310 of 868) with videos related to

Sort By:
Pageof 87
Blood|September 1, 2010
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Monette Aujay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple MyelomaXiaoyan Feng, Li Zhang, Chirag Acharya, et al.
Cancer Letters|February 28, 2002
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitorsMasaharu Akiyama, Osamu Yamada, Naotoshi Kanda, et al.
Nature Reviews. Disease Primers|July 21, 2017
Multiple myelomaShaji K Kumar, Vincent Rajkumar, Robert A Kyle, et al.
Future Oncology (London, England)|December 23, 2017
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study designPaul G Richardson, Michel Attal, Frank Campana, et al.
Blood|July 23, 2025
A BCMA-mRNA vaccine is a promising therapeutic for multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
British Journal of Haematology|December 1, 2010
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivoAjita V Singh, Madhavi Bandi, Monette A Aujay, et al.
Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.
Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.
Pageof 87